Iboga and Ibogaine: The Complete Guide

What iboga is

Tabernanthe iboga is an evergreen shrub of the Apocynaceae family, native to the forests of Gabon, Cameroon, Equatorial Guinea and the Congo basin. It grows slowly, to a few metres, and produces small yellowish-white flowers and orange fruit. Nothing about it is remarkable to look at.

What matters is underground. The root bark concentrates a family of indole alkaloids: ibogaine, ibogamine, tabernanthine, ibogaline and voacangine among them, of which ibogaine is the most abundant and the most psychoactive. The phytochemistry has been characterised in detail, and the proportions vary with the age of the plant and the part of the root. That is one reason a measured dose of bark is not a measured dose of anything.

In its home range the plant is not a drug. It is a sacrament, a medicine and a stimulant, depending on quantity: a scraping of bark to stay alert on a long hunt, a great deal of it to be initiated. The Western category of “psychedelic” maps onto it badly, and the mismatch explains a good deal of the confusion that follows.

The name travels badly too. Iboga, eboga, eboka and several other forms appear across the languages of the region, and English-language sources use them more or less at random, alongside “iboga root bark”, “iboga tree” (it is a shrub), and simply “ibogaine”, which is a different thing again. Where a page here uses one term rather than another, it is deliberate.

The plant, in detail →

Iboga, ibogaine, noribogaine

Three words that the search results treat as interchangeable. They are not, and almost every serious misunderstanding of this subject starts here.

The practical consequence is that “iboga” and “ibogaine” carry different risks, and different legal status in some countries. It also means that two people given the same milligram dose of ibogaine may end up with very different amounts of noribogaine, because CYP2D6 activity varies widely between individuals. Some people metabolise it slowly, and they are exposed for longer.

That enzyme is also where most of the drug-interaction risk sits. CYP2D6 handles a long list of common medications, several antidepressants among them, and a drug that inhibits it turns an ordinary dose of ibogaine into a larger one. This is not an exotic scenario. It describes a substantial share of the people who go looking for ibogaine in the first place.

Duration compounds it. Ibogaine itself clears over hours, while noribogaine persists for days. Someone who feels finished with the experience may still be carrying an active compound, which is why “how long does it last” has two answers, and why the days after a session are not neutral ones.

Iboga vs ibogaine, in full →

What it does, and the risk that matters

A large dose produces an oneirogenic state, a waking dream often described as reviewing one’s own life in the third person, lasting many hours and followed by a long, exhausted, reflective phase. Total duration is usually given as twenty-four to thirty-six hours. Nausea, vomiting, tremor and near-total loss of coordination are not side effects at the margins. They are what the experience is like.

That is the single most important fact on this page, and it is the one most often reduced to a footnote by people selling the treatment. People have died taking ibogaine, in clinics, in ceremonies and alone at home. The published fatality reviews point overwhelmingly at the heart, frequently compounded by pre-existing cardiac conditions, electrolyte imbalance, or other drugs taken at the same time.

Opioids are the specific danger there. Ibogaine is most sought after by people in opioid dependence, and opioids in the system during an ibogaine session are among the recognised contributing factors in reported deaths. The population most drawn to the substance overlaps precisely with the population most exposed to its worst outcome.

Beyond the heart, the acute phase carries hazards that have nothing to do with pharmacology. Ataxia during a session is severe enough that walking unassisted is not possible. Falls and aspiration during vomiting are real risks, and they are the reason someone should be awake in the room throughout rather than checking in hourly.

There is also a dose problem that no clinic can fully solve. Where the material is root bark rather than isolated ibogaine, alkaloid content varies with the age of the plant, the part of the root and the preparation. A gram of bark is not a unit of anything. This is one of the few places where the industrial version of the substance is meaningfully safer than the traditional one.

Safety, screening and contraindications →

The Bwiti tradition it comes from

Iboga is central to Bwiti, a spiritual tradition practised in Gabon and neighbouring countries, with several branches and no single orthodoxy. Its best known rite is initiation: a very large dose of root bark, taken once, in a ceremony lasting days, under the supervision of people who have done it before, and with music that structures the whole passage.

Bwiti is not one thing. Its branches differ in liturgy, in the degree of syncretism with Christianity, and in who may be initiated. Treating “Bwiti” as a single named practice is roughly as accurate as treating “church” that way. Music is not accompaniment but structure: the harp-like ngombi and the mouth bow carry the ceremony through its phases, and initiates describe the sound as the thing that makes the passage navigable.

Gabon has recognised iboga as a national heritage plant. That status is not decorative. It reflects a claim over a resource that the rest of the world has begun to want, and it sits underneath every question about who is entitled to harvest, export and profit from the species.

Bwiti, Gabon and the tradition →

What the research actually supports

The honest summary is short: the signal is real and the evidence is thin.

The Western interest begins with an accident. In 1962 a young heroin user in New York, Howard Lotsof, took ibogaine expecting a psychedelic experience and noticed afterwards that he had no withdrawal symptoms and no craving. He spent the rest of his life pursuing that observation. Nearly everything that followed, the animal studies, the clinics, the patents and the advocacy, descends from it.

Observational studies and case series have consistently reported the same thing since. A single administration sharply reduces opioid withdrawal symptoms and craving, in a way that no other single intervention does. Animal models support an effect on drug self-administration. Researchers have taken this seriously for decades, including at the US National Institute on Drug Abuse, whose 1990s programme was ended before a human efficacy trial was completed.

Recent work has extended the question beyond addiction. A Stanford study published in 2024 reported improvements in depression, anxiety and functioning among special-operations veterans with traumatic brain injury who received ibogaine with magnesium, in an observational cohort treated abroad. It is a striking result and it is not a controlled trial.

In parallel, several academic groups are pursuing analogues: compounds built around the ibogaine scaffold, designed to keep the anti-addictive effect while dropping the cardiac liability and, in some cases, the hallucinogenic effect altogether. If any of them works, the eventual medicine may not be ibogaine at all.

The distinction that matters when reading any claim about ibogaine is between acute withdrawal and long-term abstinence. They are different outcomes. The evidence is strongest for the first and weakest for the second, and providers routinely quote the first while implying the second.

Two more habits are worth acquiring before reading anything on this subject. Selection: people who travel abroad and pay for treatment are not a random sample of people with opioid dependence, and cohorts drawn from clinic clients inherit that bias whatever the results show. Follow-up: a figure quoted without a follow-up window is not an outcome. “Free of withdrawal at 72 hours” and “abstinent at twelve months” are separated by everything that actually matters.

The science, and what it does not show →

Where the law stands

In the United States, ibogaine is a Schedule I controlled substance under the Controlled Substances Act: no accepted medical use, high potential for abuse, illegal to manufacture, distribute or possess. Federal scheduling applies in every state, and state-level activity, including the research funding appropriated in Texas, does not change it.

The prohibition is older than the safety concern. The US Food and Drug Administration acted against ibogaine in the late 1960s, and the Controlled Substances Act of 1970 swept it into Schedule I alongside the rest of the psychedelics, before the anti-addictive claim had been examined and long before the cardiac mechanism was understood. The order matters. Ibogaine was not banned because it was found dangerous. It was found dangerous later, and the second fact is now used to justify the first.

Elsewhere the picture is genuinely varied. Some countries prohibit it outright. Some regulate it as a prescription medicine, New Zealand being the case most often cited. Some have never scheduled it at all and treat it as an unapproved substance by default. Gabon protects the plant itself under heritage and export rules rather than drug law. “Legal” and “unregulated” are not the same status, and the difference determines what happens to you at a border.

The United States is also where the position is moving fastest. State legislatures have begun appropriating money for ibogaine research, and the subject has acquired political sponsors it did not have five years ago. None of that reschedules anything, and a reader who confuses a research appropriation with legalisation is being encouraged to do so by people with something to sell.

Legal status changes. Every jurisdiction page on this site carries the date it was last verified, and says so on its face when that date is old.

Legal status by country →

Treatment, and how to judge a provider

Because ibogaine is prohibited in the United States and much of Europe, treatment happens elsewhere. Mexico is the most visible destination, alongside a scattering of clinics and retreats in Central America, the Caribbean, Africa and Oceania. The sector is largely unregulated. Standards range from full medical facilities with cardiologists on staff to a room with a mattress.

We publish no clinic recommendations and take no referral fees. What we publish instead is the set of questions that separates the two: what cardiac screening is performed and by whom, whether an ECG is repeated during administration, what happens in the event of an arrhythmia, how far the nearest hospital is, what the staff-to-patient ratio is overnight, and what the provider’s own record is.

A provider who cannot answer those questions precisely has answered them.

Two further things are worth knowing before comparing prices. First, what a quoted figure includes varies enormously. Medical screening, the cardiologist, the length of stay, aftercare and transport may each be in or out, and the cheapest quote is frequently the one with the least medicine in it. Second, the session is not the treatment. Reported relapse after ibogaine is common where nothing follows it, and providers who present a single administration as sufficient are describing a business model rather than a care pathway.

The treatment pathway, and what to ask →

A plant under pressure

The demand created by all of the above lands on a slow-growing wild plant with a restricted range. Harvesting the root bark can kill the individual plant, and the species does not replace itself at the speed at which it is now being taken.

This has become an organised trade. Interpol has documented iboga trafficking out of Central Africa, and the pressure is compounded by deforestation across the plant’s range. Part of the pharmaceutical response has been to look elsewhere for the raw material. Voacanga africana is already used as a precursor for semi-synthesis, and a South American species has recently been reported as another potential source.

Underneath the ecology sits a question of entitlement. The Nagoya Protocol on access and benefit-sharing exists precisely for cases like this one: a genetic resource and the traditional knowledge attached to it, held by communities in one country, turned into a product elsewhere. Whether the iboga trade ends up as an example of that framework working, or of its limits, is being decided now.

There is a version of this story in which a Gabonese sacrament is harvested to scarcity to supply clinics abroad, and the benefit accrues almost entirely to people who have never been to Gabon. It is worth naming that possibility while it is still a possibility.

Conservation, trafficking and reciprocity →

What people report

The published literature is thin. The volume of first-hand account is not. Most of what circulates about ibogaine comes from people who have taken it, and Reddit is now one of the most consulted sources on the subject, including by the generative engines answering questions about it.

The accounts converge on some things and diverge sharply on others. The oneirogenic phase, the sense of reviewing one’s own history, the physical wretchedness, the exhaustion afterwards: these recur. What follows in the weeks after does not. Some describe a durable break, others a window of a few weeks that closed. Both are honest reports of the same intervention.

Microdosing is a separate practice with a separate evidence base, which is to say almost none. Small repeated doses are used for mood and focus rather than for withdrawal, and the cardiac question does not disappear at low dose. It becomes harder to see.

We publish accounts attributed and with documented consent, and we never use one to support a clinical claim. They answer a different question: not “does this work” but “what is this like”.

First-hand accounts and integration →

Why this is moving now

Interest in ibogaine has risen sharply, and the rise is political as much as medical. Search interest across every major market multiplied several-fold in the spring of 2026, in a spike that was global and simultaneous, which is the signature of news rather than of gradual discovery.

Three forces are behind it. State legislatures in the United States have begun funding ibogaine research directly, with Texas the largest and most visible. Veterans’ organisations have become effective advocates, carrying the traumatic brain injury findings into legislatures that had no interest in psychedelics as such. And investors have arrived: there are now listed companies whose value depends on ibogaine or its analogues reaching approval.

None of that is evidence about the substance. It is evidence about attention, and attention is what turns a marginal subject into a market. It also means the information environment is getting worse rather than better: more sources, more confident, with more at stake in what you conclude.

Policy, research and the news thread →

If you are considering it

Two pages are worth reading before any other: cardiac risk, which explains what the screening is for, and side effects, which describes what the days around a session are actually like.

Neither will tell you whether ibogaine is safe for you. Nobody writing on the internet can. What they will give you is the list of things a competent provider must know about you before agreeing to administer anything, and the questions to ask when one does not.